CN115151639A - 靶向磷脂酰肌醇蛋白聚糖3（gpc3）的抗体和嵌合抗原受体及其使用方法 - Google Patents

靶向磷脂酰肌醇蛋白聚糖3（gpc3）的抗体和嵌合抗原受体及其使用方法 Download PDF

Info

Publication number
CN115151639A
CN115151639A CN202180016268.2A CN202180016268A CN115151639A CN 115151639 A CN115151639 A CN 115151639A CN 202180016268 A CN202180016268 A CN 202180016268A CN 115151639 A CN115151639 A CN 115151639A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
domain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180016268.2A
Other languages
English (en)
Chinese (zh)
Inventor
范晓虎
毛杰
庄秋传
王瑞雪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Legend Biotechnology Co Ltd
Original Assignee
Nanjing Legend Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Legend Biotechnology Co Ltd filed Critical Nanjing Legend Biotechnology Co Ltd
Publication of CN115151639A publication Critical patent/CN115151639A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
CN202180016268.2A 2020-02-27 2021-02-26 靶向磷脂酰肌醇蛋白聚糖3（gpc3）的抗体和嵌合抗原受体及其使用方法 Pending CN115151639A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/076937 2020-02-27
CN2020076937 2020-02-27
PCT/CN2021/078203 WO2021170100A1 (en) 2020-02-27 2021-02-26 Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof

Publications (1)

Publication Number Publication Date
CN115151639A true CN115151639A (zh) 2022-10-04

Family

ID=77490732

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180016268.2A Pending CN115151639A (zh) 2020-02-27 2021-02-26 靶向磷脂酰肌醇蛋白聚糖3（gpc3）的抗体和嵌合抗原受体及其使用方法

Country Status (12)

Country Link
US (1) US20230088461A1 (enExample)
EP (1) EP4110912A4 (enExample)
JP (1) JP7747645B2 (enExample)
KR (1) KR20220146456A (enExample)
CN (1) CN115151639A (enExample)
AU (1) AU2021225978A1 (enExample)
BR (1) BR112022016958A2 (enExample)
CA (1) CA3170023A1 (enExample)
IL (1) IL295774A (enExample)
MX (1) MX2022010360A (enExample)
WO (1) WO2021170100A1 (enExample)
ZA (1) ZA202209069B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260116991A1 (en) * 2021-02-03 2026-04-30 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Monoclonal antibody for specifically recognizing glypican-3, and application thereof
JP2024507958A (ja) * 2021-02-26 2024-02-21 ナンジン レジェンド バイオテック カンパニー，リミテッド 外因的に導入されたサイトカインを発現する操作された免疫エフェクター細胞
JP2025524921A (ja) * 2022-07-29 2025-08-01 レジェンド バイオテック アイルランド リミテッド 細胞療法の持続性を促進するための方法
EP4562046A1 (en) * 2022-07-29 2025-06-04 Legend Biotech Ireland Limited Claudin-6 binding moieties and uses thereof
CN117025541B (zh) * 2023-08-15 2025-10-17 福建医科大学附属协和医院 一种靶向b7-h3并共表达细胞因子和趋化因子的car-t细胞及其用途
KR20250116580A (ko) * 2024-01-24 2025-08-01 국립암센터 Gpc3에 특이적으로 결합하는 신규 항체를 이용한 키메라 항원 수용체 t 세포

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170281683A1 (en) * 2014-09-26 2017-10-05 Baylor College Of Medicine Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
CN107428833A (zh) * 2015-01-16 2017-12-01 朱诺治疗学股份有限公司 Ror1特异性抗体和嵌合抗原受体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050020806A (ko) * 2002-05-23 2005-03-04 써니브룩 앤드 우먼스 칼리지 헬스 사이언시즈 센터 간세포암의 진단
CN1894587A (zh) * 2003-10-29 2007-01-10 财团法人熊本高新技术产业财团 恶性黑色素瘤(melanoma)的诊断试剂
AU2005256113B2 (en) 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
US7723043B2 (en) * 2006-01-04 2010-05-25 Picobella, Lp Methods for screening for prostate cancer
CN104520331B (zh) * 2012-06-01 2018-09-07 美国政府(由卫生和人类服务部的部长所代表) 磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途
JP2017522861A (ja) 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド 抗ｇｐｃ３抗体及びイムノコンジュゲート
WO2018059549A1 (en) * 2016-09-30 2018-04-05 Novartis Ag Immune effector cell therapies with enhanced efficacy
TWI831365B (zh) * 2017-01-10 2024-02-01 國立大學法人山口大學 抗ｇｐｃ３抗體
EP3615574B1 (en) 2017-04-26 2026-06-24 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
CN109385400A (zh) * 2017-08-09 2019-02-26 科济生物医药（上海）有限公司 共表达pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
AR114112A1 (es) * 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
WO2020017479A1 (ja) 2018-07-17 2020-01-23 ノイルイミューン・バイオテック株式会社 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
CN110684120B (zh) * 2019-10-12 2023-03-07 华夏源（上海）细胞基因工程股份有限公司 一种靶向gpc3的嵌合抗原受体及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170281683A1 (en) * 2014-09-26 2017-10-05 Baylor College Of Medicine Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
CN107428833A (zh) * 2015-01-16 2017-12-01 朱诺治疗学股份有限公司 Ror1特异性抗体和嵌合抗原受体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吴荻;崔久嵬;于鸿;: "黑素瘤的免疫治疗研究进展", 细胞与分子免疫学杂志, no. 02, 18 February 2016 (2016-02-18) *

Also Published As

Publication number Publication date
EP4110912A4 (en) 2024-07-10
ZA202209069B (en) 2023-10-25
AU2021225978A1 (en) 2022-09-08
KR20220146456A (ko) 2022-11-01
CA3170023A1 (en) 2021-09-02
US20230088461A1 (en) 2023-03-23
WO2021170100A1 (en) 2021-09-02
EP4110912A1 (en) 2023-01-04
MX2022010360A (es) 2022-09-21
BR112022016958A2 (pt) 2022-10-25
JP2023516286A (ja) 2023-04-19
JP7747645B2 (ja) 2025-10-01
IL295774A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
CN114981305A (zh) Claudin18.2结合部分及其用途
JP7747645B2 (ja) グリピカン－３（ｇｐｃ３）を標的化する抗体及びキメラ抗原受容体並びにその使用方法
US20260027209A1 (en) Claudin-6 binding moieties and uses thereof
CN115052901A (zh) 靶向bcma的单结构域抗体和嵌合抗原受体及其使用方法
CN114981303B (zh) 人源化抗Claudin18.2（CLDN18.2）抗体
WO2022127871A1 (en) Gucy2c binding molecules and uses thereof
WO2024041650A1 (en) Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
WO2022012680A1 (en) Cd20 binding molecules and uses thereof
WO2025067338A1 (en) Dll3 binding moieties and uses thereof
WO2024067762A1 (en) Antibody and chimeric antigen receptors targeting gcc and methods of use thereof
WO2026103881A1 (en) Bcma binding moieties and uses thereof
HK40079774A (en) Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof
HK40075690A (en) Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof
HK40075456A (en) Claudin18.2 binding moieties and uses thereof
EA049821B1 (ru) Связывающие gucy2c молекулы и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079774

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination